<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120430009593N15</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-01</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Effect  of intravenous Dexmedetomidine and Dexamethasone on spinal anesthesia in opium addicted patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison between intravenous Dexamethasone and Dexmedtomidine  on spinal anesthesia level in opium addicted patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>27</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59785</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method :
 Randomization :  Simple 
Randomization Unit: based on patient 
 Randomization Tool: Random Number Table - Block stratified randomization software window version 6.0.
 Using this software, a random number table will be  created and accordingly , the sample  will be  divided into two groups of 30 patients  in such a way that at the beginning of each person's entry, his / her number will be matched with the table so the type of group,  dexmedetomidine or dexamethasone , will be specified.
The participants will not aware of the allocation of groups and  won't know that the study will have  two groups. The drugs will be given by first  anesthesiologist  who  knows the groups. The person who will assess the outcome (the second anesthesiologist ) also won't be aware of the group , Blinding description: The person performing the spinal anesthesia,  is the same person who will evaluate the spinal levels and does not know about the group .The patients 
 also does not know the type of group. Another anesthesiologist who knows the type of drugs and the group will give the drugs.</study_design>
      <phase>3</phase>
      <hc_freetext>Dexmedetomidine and Dexamethasone on Spinal Anesthesia Level  in Opium Addicted Patients.</hc_freetext>
      <i_freetext>Intervention 1: Control group : Dexamethasone 8 mg 10 minutes before spinal anesthesia with bupivacaine and then normal saline infusion  at a rate of 0.5 μg / kg / hr during surgery. Each Dexamesthasone ampule consists of  8 mg  and belongs to Alborz Drug Company. Intervention 2: Intervention group : Dexmedetomidine infusion at a dose of 0.5 micrograms per kilogram of body weight for 10 minutes before spinal anesthesia and then infusion at a dose of 0.5 micrograms per kilogram of body weight.Each Dexmedtomidine vial consists of  2 c.c (200microgram )and belongs to  Exir Drug  company.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information about the main and secondary outcome without the names of the people

When:
Start the access period immediately after printing the results

To whom:
Only for researchers working in academic and scientific institutions

Conditions:
request data via email

Where to obtain:
Send email to the scientific director of research

How to obtain:
After sending an email to the scientific director of the research and stating the reason for the request, the documents will be sent within 3 months

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elham Memary</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>operating room, ground floor,Imam Hossein Hospital, Shahid Madani St.,Imam Hossein Square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1617763141</zip>
        <telephone>00982173430</telephone>
        <email>drmemary@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elham Memary</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>operating room, ground floor,Imam Hossein Hospital, Shahid Madani St.,Imam Hossein Square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1617763141</zip>
        <telephone>00982173430</telephone>
        <email>drmemary@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with drug addiction
Patients with ASA class 1,2
Patients with BMI &lt;30
Patients aged 18 to 65 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant patients
Patients with dissatisfaction with spinal anesthesia
Patients with coagulation disorders
Patients with a history of multiple sclerosis
Patients with local infection in the lumbar region
Patients with allergies to local anesthetics
Patients with systemic infections
Patients with diabetic neuropathy
Patients with bradycardia with less than 50 HR</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group : Dexamethasone 8 mg 10 minutes before spinal anesthesia with bupivacaine and then normal saline infusion  at a rate of 0.5 μg / kg / hr during surgery. Each Dexamesthasone ampule consists of  8 mg  and belongs to Alborz Drug Company</i_keyword>
      <i_keyword>Intervention group : Dexmedetomidine infusion at a dose of 0.5 micrograms per kilogram of body weight for 10 minutes before spinal anesthesia and then infusion at a dose of 0.5 micrograms per kilogram of body weight.Each Dexmedtomidine vial consists of  2 c.c (200microgram )and belongs to  Exir Drug  company</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Onset of  Sensory Block. Timepoint: Every 3 Minutes to 15 Minutes and then Every 5 Minutes to 30 Minutes and Every 15 Minutes to 2 Hours. Method of measurement: Pinprick Test.</prim_outcome>
      <prim_outcome>Onset of Motor Block. Timepoint: Every 3 Minutes to 15 Minutes and then Every 5 Minutes to 30 Minutes and Every 15 Minutes to 2 Hours. Method of measurement: Bromage Scale.</prim_outcome>
      <prim_outcome>Duration  of Motor Block. Timepoint: Every 3 Minutes to 15 Minutes and then Every 5 Minutes to 30 Minutes and Every 15 Every to 2 Hours. Method of measurement: Bromage Scale.</prim_outcome>
      <prim_outcome>Regression of  Two Level of Sensory Block. Timepoint: Every 3 Minutes to 15 Minutes and then Every 5 Minutes to 30 Minutes and Every 15 Minutes to 2 hours. Method of measurement: Pinprick Test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Total Analgesia Time. Timepoint: Every 3 Minutes to 15 Minutes and then Every 5 Minutes to 30 Minutes and Every 15 Minutes to 2 Hours. Method of measurement: ََAccording to Time  with Visual Analogue Scale less than 3.</sec_outcome>
      <sec_outcome>The First Time for Analgesia Requirement. Timepoint: Every 3 Minutes to 15 Minutes and then Every 5 Minutes to 30 Minutes and Every 15 Minutes to 2 Hours. Method of measurement: Analgesic  Request According to VAS More than 3.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-07-13</approval_date>
        <contact_name>Ethics committee of ShahidBeheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Chamran Highway, Yemen St., next to Taleghani Hospital, Shahid Beheshti University of Medical Sciences Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
